{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T13:50:46Z","timestamp":1772286646699,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00737-025-01639-1","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:18:10Z","timestamp":1768457890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Informed consent and contraception when prescribing valproate to individuals of childbearing potential: a quality improvement project"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-8843","authenticated-orcid":false,"given":"Mariella","family":"Suleiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Jarahzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Belikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himani","family":"Jani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7332-4757","authenticated-orcid":false,"given":"Maria","family":"Bodic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulette","family":"Ginsburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2654-5071","authenticated-orcid":false,"given":"Theresa","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-6094","authenticated-orcid":false,"given":"Sara V.","family":"Carlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"1639_CR1","unstructured":"(WHO), W. H. O (2023) Statement on the risks associated with valproic acid (sodium valproate) in women and girls of childbearing potential. WHO. Retrieved June 19th from www.who.int\/news\/item\/02-05-2023-use-of-valproic-acid-in-women-and-girls-of-childbearing-potential"},{"key":"1639_CR2","unstructured":"AbbVie I Depakote (divalproex sodium) [package insert] (n.d.). U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/018723s068lbl.pdf. Revised 03\/2024. Accessed 01\/26\/2025"},{"issue":"4","key":"1639_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/eip.12688","volume":"13","author":"AY Adan Sanchez","year":"2019","unstructured":"Adan Sanchez AY, McMillan E, Bhaduri A, Pehlivan N, Monson K, Badcock P, Thompson K, Killackey E, Chanen A, O\u2019Donoghue B (2019) High-risk sexual behaviour in young people with mental health disorders. Early Interv Psychiatry 13(4):867\u2013873. https:\/\/doi.org\/10.1111\/eip.12688","journal-title":"Early Interv Psychiatry"},{"key":"1639_CR4","unstructured":"Administration UFD (2011) FDA Drug Safety Communication:\u00a0Children born to mothers who took Valproate products while pregnant may have impaired cognitive development."},{"key":"1639_CR5","unstructured":"Administration UFD (2013) FDA Drug Safety Communication:\u00a0Valproate Anti-seizure Products Contraindicated for Migraine Prevention\u00a0in Pregnant Women due to Decreased IQ Scores in Exposed Children. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-valproate-anti-seizure-products-contraindicated-migraine-prevention#tabs-1."},{"key":"1639_CR6","unstructured":"Administration USFD (2015) Valproate Information. US FDA. Retrieved June 19th from www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/valproate-information"},{"key":"1639_CR7","unstructured":"Agency M (2018) a. H. p. R. Valproate medicines (Epilim\u25bc Depakote\u25bc): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met. Drug Saf Update 11>(9). https:\/\/www.gov.uk\/drug-safety-update\/valproate-medicines-epilim-depakote-contraindicated-in-women-and-girls-of-childbearing-potential-unless-conditions-of-pregnancy-prevention-programme-are-met#post-publication-note---january-2024"},{"issue":"2","key":"1639_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eurpsy.2007.08.001","volume":"23","author":"NA Aliyev","year":"2008","unstructured":"Aliyev NA, Aliyev ZN (2008) Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry 23(2):109\u2013114. https:\/\/doi.org\/10.1016\/j.eurpsy.2007.08.001","journal-title":"Eur Psychiatry"},{"issue":"10","key":"1639_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003945.pub4","volume":"10","author":"SF Baillon","year":"2018","unstructured":"Baillon SF, Narayana U, Luxenberg JS, Clifton AV (2018) Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 10(10):Cd003945. https:\/\/doi.org\/10.1002\/14651858.CD003945.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1639_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10995-016-2155-1","volume":"21","author":"AM Branum","year":"2017","unstructured":"Branum AM, Ahrens KA (2017) Trends in timing of pregnancy awareness among US women. Matern Child Health J 21(4):715\u2013726. https:\/\/doi.org\/10.1007\/s10995-016-2155-1","journal-title":"Matern Child Health J"},{"issue":"6","key":"1639_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/jnnp-2012-304270","volume":"84","author":"RL Bromley","year":"2013","unstructured":"Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, Garc\u00eda-Fi\u00f1ana M, Kneen R, Lucas SB, Shallcross R, Baker GA, Group L (2013) The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry 84(6):637\u2013643 a. M. N. https:\/\/doi.org\/10.1136\/jnnp-2012-304270","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1639_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1136\/jnnp-2013-306318","volume":"85","author":"E Campbell","year":"2014","unstructured":"Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, Liggan B, Irwin B, Delanty N, Hunt SJ, Craig J, Morrow J (2014) Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland epilepsy and pregnancy registers. J Neurol Neurosurg Psychiatry 85(9):1029\u20131034. https:\/\/doi.org\/10.1136\/jnnp-2013-306318","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1639_CR13","doi-asserted-by":"publisher","unstructured":"Casassus B (2017) France bans sodium valproate use in case of pregnancy. Lancet 390(10091):217. https:\/\/doi.org\/10.1016\/S0140-6736(17)31866-4","DOI":"10.1016\/S0140-6736(17)31866-4"},{"issue":"16","key":"1639_CR14","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","volume":"309","author":"J Christensen","year":"2013","unstructured":"Christensen J, Gr\u00f8nborg TK, S\u00f8rensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M (2013) Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309(16):1696\u20131703. https:\/\/doi.org\/10.1001\/jama.2013.2270","journal-title":"JAMA"},{"issue":"1","key":"1639_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13023-019-1064-y","volume":"14","author":"J Clayton-Smith","year":"2019","unstructured":"Clayton-Smith J, Bromley R, Dean J, Journel H, Odent S, Wood A, Williams J, Cuthbert V, Hackett L, Aslam N, Malm H, James G, Westbom L, Day R, Ladusans E, Jackson A, Bruce I, Walker R, Sidhu S, Turnpenny P (2019) Diagnosis and management of individuals with fetal valproate spectrum disorder; a consensus statement from the European reference network for congenital malformations and intellectual disability. Orphanet J Rare Dis 14(1):180. https:\/\/doi.org\/10.1186\/s13023-019-1064-y","journal-title":"Orphanet J Rare Dis"},{"key":"1639_CR16","doi-asserted-by":"publisher","unstructured":"Committee Opinion 762 ACOG (2019) Prepregnancy counseling. Obstet Gynecol 133(1):e78\u2013e89. https:\/\/doi.org\/10.1097\/aog.0000000000003013","DOI":"10.1097\/aog.0000000000003013"},{"issue":"4","key":"1639_CR17","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.clinthera.2020.02.007","volume":"42","author":"KE Crowley","year":"2020","unstructured":"Crowley KE, Urben L, Hacobian G, Geiger KL (2020) Valproic acid for the management of agitation and delirium in the intensive care setting: a retrospective analysis. Clin Ther 42(4):e65\u2013e73. https:\/\/doi.org\/10.1016\/j.clinthera.2020.02.007","journal-title":"Clin Ther"},{"issue":"4","key":"1639_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/0190-9622(92)70088-w","volume":"26","author":"WS Dai","year":"1992","unstructured":"Dai WS, LaBraico JM, Stern RS (1992) Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 26(4):599\u2013606. https:\/\/doi.org\/10.1016\/0190-9622(92)70088-w","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"1639_CR19","doi-asserted-by":"publisher","first-page":"e2163","DOI":"10.1212\/wnl.0000000000200260","volume":"98","author":"A Degremont","year":"2022","unstructured":"Degremont A, Kerbrat S, Balusson F, Jonville-Bera AP, Ringa V, Travers D, Tillaut H, Leray E, Oger E, Biraben A, Polard E (2022) Prescribing trends for valproate among pregnant women: a cross-sectional study in 2013 and 2016 using the French health insurance database. Neurology 98(21):e2163\u2013e2173. https:\/\/doi.org\/10.1212\/wnl.0000000000200260","journal-title":"Neurology"},{"issue":"5","key":"1639_CR20","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.9966","volume":"21","author":"CC Draghici","year":"2021","unstructured":"Draghici CC, Miulescu RG, Petca RC, Petca A, Dumitra\u0219cu MC, \u0218andru F (2021) Teratogenic effect of isotretinoin in both fertile females and males (Review). Exp Ther Med 21(5):534. https:\/\/doi.org\/10.3892\/etm.2021.9966","journal-title":"Exp Ther Med"},{"key":"1639_CR21","doi-asserted-by":"publisher","unstructured":"Fauvelle K, Bigna JJ (2023) Compliance with prescribing and dispensing conditions for valproate and related substances in girls and women of childbearing potential: a survey of community pharmacists in France. Drug Saf 46(2):121\u2013128. https:\/\/doi.org\/10.1007\/s40264-022-01234-8. Erratum in: Drug Saf 46(3):323. https:\/\/doi.org\/10.1007\/s40264-022-01268-y.\u00a0https:\/\/doi.org\/10.1007\/s40264-022-01234-8","DOI":"10.1007\/s40264-022-01234-8"},{"issue":"4","key":"1639_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4088\/JCP.15m10046","volume":"77","author":"D Gotlib","year":"2016","unstructured":"Gotlib D, Perelstein E, Kurlander J, Zivin K, Riba M, Muzik M (2016) Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review. J Clin Psychiatry 77(4):527\u2013534. https:\/\/doi.org\/10.4088\/JCP.15m10046","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1639_CR23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00702-022-02542-0","volume":"129","author":"G Hefner","year":"2022","unstructured":"Hefner G, Wolff J, Toto S, Rei\u00dfner P, Klimke A (2022) Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. J Neural Transm (Vienna) 129(11):1353\u20131365. https:\/\/doi.org\/10.1007\/s00702-022-02542-0","journal-title":"J Neural Transm (Vienna)"},{"issue":"10","key":"1639_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1212\/01.wnl.0000344167.78102.f0","volume":"72","author":"AG Herzog","year":"2009","unstructured":"Herzog AG, Blum AS, Farina EL, Maestri XE, Newman J, Garcia E, Krishnamurthy KB, Hoch DB, Replansky S, Fowler KM, Smithson SD, Dworetzky BA, Bromfield EB (2009) Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 72(10):911\u2013914. https:\/\/doi.org\/10.1212\/01.wnl.0000344167.78102.f0","journal-title":"Neurology"},{"issue":"3","key":"1639_CR25","doi-asserted-by":"publisher","first-page":"e92573","DOI":"10.1371\/journal.pone.0092573","volume":"9","author":"E Horowitz","year":"2014","unstructured":"Horowitz E, Bergman LC, Ashkenazy C, Moscona-Hurvitz I, Grinvald-Fogel H, Magnezi R (2014) Off-label use of sodium valproate for schizophrenia. PLoS One 9(3):e92573. https:\/\/doi.org\/10.1371\/journal.pone.0092573","journal-title":"PLoS One"},{"issue":"2","key":"1639_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003499.pub3","volume":"2010","author":"N Huband","year":"2010","unstructured":"Huband N, Ferriter M, Nathan R, Jones H (2010) Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev 2010(2):Cd003499. https:\/\/doi.org\/10.1002\/14651858.CD003499.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1639_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/1096-8628(20010115)98:2<168::AID-AJMG1026>3.0.CO;2-O","volume":"98","author":"C Kozma","year":"2001","unstructured":"Kozma C (2001) Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 98(2):168\u2013175","journal-title":"Am J Med Genet"},{"issue":"2","key":"1639_CR28","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1192\/bjo.2022.18","volume":"8","author":"B Limbu","year":"2022","unstructured":"Limbu B, Deb S, Roy M, Lee R, Roy A, Taiwo O (2022) Randomised controlled trials of mood stabilisers for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open 8(2):e52. https:\/\/doi.org\/10.1192\/bjo.2022.18","journal-title":"BJPsych Open"},{"issue":"3","key":"1639_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","volume":"12","author":"KJ Meador","year":"2013","unstructured":"Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, Group, N. S. (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12(3):244\u2013252. https:\/\/doi.org\/10.1016\/S1474-4422(12)70323-X","journal-title":"Lancet Neurol"},{"issue":"2","key":"1639_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40596-017-0672-x","volume":"42","author":"LM Osborne","year":"2018","unstructured":"Osborne LM, MacLean JV, Barzilay EM, Meltzer-Brody S, Miller L, Yang SN (2018) Reproductive psychiatry residency training: a survey of psychiatric residency program directors. Acad Psychiatry 42(2):197\u2013201. https:\/\/doi.org\/10.1007\/s40596-017-0672-x","journal-title":"Acad Psychiatry"},{"issue":"3","key":"1639_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/08897077.2019.1635962","volume":"41","author":"M Paino","year":"2020","unstructured":"Paino M, Aletraris L, Roman PM (2020) The use of off-label medications in substance abuse treatment programs. Subst Abus 41(3):340\u2013346. https:\/\/doi.org\/10.1080\/08897077.2019.1635962","journal-title":"Subst Abus"},{"key":"1639_CR32","doi-asserted-by":"publisher","unstructured":"Practice Bulletin No. 187: Neural Tube Defects (2017) Obstet Gynecol, 130(6), e279-e290. https:\/\/doi.org\/10.1097\/aog.0000000000002412","DOI":"10.1097\/aog.0000000000002412"},{"key":"1639_CR33","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3389\/fpsyt.2020.00739","volume":"11","author":"A Rakitin","year":"2020","unstructured":"Rakitin A (2020) Why do psychiatrists still prescribe valproate to women of childbearing potential? Front Psychiatry 11:739. https:\/\/doi.org\/10.3389\/fpsyt.2020.00739","journal-title":"Front Psychiatry"},{"issue":"5","key":"1639_CR34","first-page":"12","volume":"28","author":"J Schaeffer","year":"2016","unstructured":"Schaeffer J (2016) Poor documentation: why it happens and how to fix it. Record 28(5):12. https:\/\/www.fortherecordmag.com\/archives\/0516p12.shtml","journal-title":"Record"},{"issue":"5","key":"1639_CR35","doi-asserted-by":"publisher","first-page":"e2412680","DOI":"10.1001\/jamanetworkopen.2024.12680","volume":"7","author":"NE Smolinski","year":"2024","unstructured":"Smolinski NE, Sarayani A, Thai TN, Jugl S, Ewig CLY, Winterstein AG (2024) Prenatal exposure to valproic acid across various indications for use. JAMA Netw Open 7(5):e2412680. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.12680","journal-title":"JAMA Netw Open"},{"key":"1639_CR36","doi-asserted-by":"publisher","unstructured":"Suleiman M, Silver DF, Forray A, Goodsmith N (2025) Beyond the Boxed Warning: A Call for Regulation of Psychiatry\u2019s Most Teratogenic Drug. J Clin Psychiatry 86(4). https:\/\/doi.org\/10.4088\/JCP.25com16026","DOI":"10.4088\/JCP.25com16026"},{"issue":"4","key":"1639_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/cpt.158","volume":"98","author":"M Tanoshima","year":"2015","unstructured":"Tanoshima M, Kobayashi T, Tanoshima R, Beyene J, Koren G, Ito S (2015) Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta-analysis. Clin Pharmacol Ther 98(4):417\u2013441. https:\/\/doi.org\/10.1002\/cpt.158","journal-title":"Clin Pharmacol Ther"},{"key":"1639_CR38","unstructured":"The iPLEDGE REMS Prescriber Guide. (2023) https:\/\/ipledgeprogram.com\/#Main\/Resources"},{"issue":"Pt A","key":"1639_CR39","doi-asserted-by":"publisher","first-page":"107569","DOI":"10.1016\/j.yebeh.2020.107569","volume":"114","author":"FJE Vajda","year":"2021","unstructured":"Vajda FJE, O\u2019Brien TJ, Graham JE, Hitchcock AA, Perucca P, Lander CM, Eadie MJ (2021) Folic acid dose, valproate, and fetal malformations. Epilepsy Behav 114(Pt A):107569. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107569","journal-title":"Epilepsy Behav"},{"issue":"7","key":"1639_CR40","doi-asserted-by":"publisher","first-page":"e017248","DOI":"10.1136\/bmjopen-2017-017248","volume":"7","author":"AA Veroniki","year":"2017","unstructured":"Veroniki AA, Rios P, Cogo E, Straus SE, Finkelstein Y, Kealey R, Reynen E, Soobiah C, Thavorn K, Hutton B, Hemmelgarn BR, Yazdi F, D\u2019Souza J, MacDonald H, Tricco AC (2017) Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open 7(7):e017248. https:\/\/doi.org\/10.1136\/bmjopen-2017-017248","journal-title":"BMJ Open"},{"issue":"11","key":"1639_CR41","doi-asserted-by":"publisher","first-page":"CD010224","DOI":"10.1002\/14651858.CD010224.pub2","volume":"11","author":"J Weston","year":"2016","unstructured":"Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, Hounsome J, McKay AJ, Tudur Smith C, Marson AG (2016) Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 11(11):CD010224. https:\/\/doi.org\/10.1002\/14651858.CD010224.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-025-01639-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00737-025-01639-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-025-01639-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:24:39Z","timestamp":1772000679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00737-025-01639-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1007\/s00737-025-01639-1","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed by the Maimonides Health Institutional Review Board and determined to be a Healthcare operation, not research, and therefore deemed exempt. MMC IRB # 2022-11-09.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical publication statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declaration"}},{"value":"The authors have no financial disclosures or conflict of interests to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/disclosure"}}],"article-number":"18"}}